Posted in Pharmaceuticals and Healthcare, Total Reads: 1759
SWOT Analysis of GW Pharmaceuticals with USP, Competition, STP (Segmentation, Targeting, Positioning) - Marketing Analysis
Its MS treatment product
People suffering from multiple sclerosis, epilepsy and cancer
Focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform
1. GW Pharmaceuticals has the only cultivation license in the United Kingdom from the Home Office and theMHRA, to cultivate cannabis from seeds and clones to conduct scientific research concerning the medicinal uses of the plant 2. GW Pharmaceuticals concluded a partnership with Bayer for the distribution of Sativex in North America 3. GW is researching a large number of cannabinoids, each of which has different effects and applications
4.Collaboration with various educational institutes for R&D.
5. Strong expertise in the industry
1. Health issues due to side effects of cannabis 2.Human rights issues as cannabis is considered as a harmful drug 3.Legal issues in cultivating medical cannabis
4.Requires very high quality control in cultivating medical cannabis
1. Its cannabis-based product, Epidiolex, developed for experimental treatment of epilepsy, will undergo stage-two trials in the US in 2014 2. Tie ups with large hospitals can be a huge opportunity 3.Scope of entering into other segments of pharmaceuticals
1.It has only one major drug Sativex, contribute maximum to the revenue 2.Need for continuous innovation 3.Stringent government rules and quality control measures
1.Shire UK 2.Teva UK Limited 3.Meda Pharmaceuticals UK
The brandnames and other brand information used in the brandguide section are properties of their respective companies. The companies are not associated with MBASkool in any way. The brand names are used purely for educational/academic purpose only. Utmost Care has been taken in the analysis of the brands. However, if you find any ambiguity kindly help us improve.